stockmarketproxy
/
NBIXNasdaq SEC EDGAR

NEUROCRINE BIOSCIENCES INC

Biological Products, (No Diagnostic Substances)·SAN DIEGO, CA·FY end 12/31·CIK 914475
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$2.9B$2.4B$1.9B$1.5B$1.1B
Gross Profit——————
Operating Income$619.1M$570.5M$250.9M$249.0M$102.5M
Net Income$478.6M$341.3M$249.7M$154.5M$89.6M
Operating CF$782.7M$595.4M$389.9M$339.4M$256.5M
Capex$34.0M$38.2M$28.3M$16.5M$23.4M
Free Cash Flow$748.7M$557.2M$361.6M$322.9M$233.1M
Buybacks$167.7M$300.0M———
Dividends——————
Gross Margin——————
Operating Margin21.6%24.2%13.3%16.7%9.0%
Net Margin16.7%14.5%13.2%10.4%7.9%
FCF Margin26.2%23.7%19.2%21.7%20.6%
R&D / Revenue——————
Effective Tax32.2%29.8%24.8%27.8%11.6%
Debt / Equity——————
Buybacks / FCF22.4%53.8%———

Peer comparison

Biological Products, (No Diagnostic Substances) · 5 peers
CEO Pay Ratio
NBIX
49:1
EXEL
81:1
GILD
119:1
BIIB
113:1
PCVX
48:1
IBRX
69:1
CEO total comp
NBIX
—
EXEL
$33M
GILD
$28M
BIIB
$24M
PCVX
$14M
IBRX
$13M
Net Margin
NBIX
16.7%
EXEL
33.7%
GILD
28.9%
BIIB
13.1%
PCVX
—
IBRX
-310.2%